Viridian Therapeutics, Inc.

Total Valuation

Viridian Therapeutics, Inc. carries a market capitalization of 1.43B, placing it among publicly traded companies globally. Its enterprise value stands at 1.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Viridian Therapeutics, Inc. currently has 102.46M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 24.82, and the price-to-book ratio stands at -1.22.

Enterprise Valuation

Financial Position

Viridian Therapeutics, Inc. maintains a current ratio of 15.15, meaning it holds 15.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.05, indicating elevated leverage, while an interest coverage ratio of -49.28 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Viridian Therapeutics, Inc.'s stock has gained approximately 9.82699% over the past 52 weeks. The 50-day moving average sits at 17.13, while the 200-day moving average is 24.29.

Income Statement

Over the trailing twelve months, Viridian Therapeutics, Inc. generated 70.92M in revenue and converted that into -360.59M in net income, yielding earnings per share of -4.01. EBITDA reached -385.23M, while operating income came in at -385.70M.

Balance Sheet

Viridian Therapeutics, Inc. holds 762.18M in cash and equivalents against 51.17M in total debt, resulting in a net debt position of -125.91M. Total book value stands at -1.44B, with working capital of 732.94M providing operational flexibility.

Cash Flow

Viridian Therapeutics, Inc. produced -303.39M in operating cash flow over the past twelve months. After subtracting -432,000.00 in capital expenditures, free cash flow totaled -303.82M - equivalent to -3.38 per share.

Margins

Viridian Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -543.86 and net profit margin of -508.46 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Viridian Therapeutics, Inc.'s most recent stock split took place on November 13, 2020 with a 15:1 split ratio.

Scores

Viridian Therapeutics, Inc. posts an Altman Z-Score of 3.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.